Two Center One Goal

Production Center

Xindu Biological, Xinhua International plans to build a biotransformation mycelium production line with the scale of an annual output of 50 tons. Its parent company (Xinquan Xinlin) used 30 years of experience to successfully develop a new advanced technology of, with full intellectual property rights, “biotransformation, directed cultivation" to produce biological mycelium raw materials for health products.

The procedure uses biotransformation, directed cultivation, low-temperature extraction, and sterile docking high-tech core technology. During the biotransformation growth of mycelium, by-products of valuable active ingredients are produced, which are needed by the human body but difficult to obtain. They can be widely used as raw materials for all kinds of health products, and the market prospects are very promising.